vs

Side-by-side financial comparison of AST SpaceMobile, Inc. (ASTS) and PUMA BIOTECHNOLOGY, INC. (PBYI). Click either name above to swap in a different company.

PUMA BIOTECHNOLOGY, INC. is the larger business by last-quarter revenue ($75.5M vs $54.3M, roughly 1.4× AST SpaceMobile, Inc.). On growth, AST SpaceMobile, Inc. posted the faster year-over-year revenue change (2758.2% vs 27.7%). PUMA BIOTECHNOLOGY, INC. produced more free cash flow last quarter ($14.4M vs $-330.7M).

AST SpaceMobile, Inc. is a publicly traded satellite designer and manufacturer based in Midland, Texas, United States. The company is building the SpaceMobile satellite constellation, a space-based cellular broadband network designed to connect directly to standard, unmodified smartphones. The network is intended to deliver 4G and 5G broadband coverage globally, particularly in remote and underserved regions.

Puma Biotechnology is a publicly traded biopharmaceutical company headquartered in Los Angeles, CA.

ASTS vs PBYI — Head-to-Head

Bigger by revenue
PBYI
PBYI
1.4× larger
PBYI
$75.5M
$54.3M
ASTS
Growing faster (revenue YoY)
ASTS
ASTS
+2730.4% gap
ASTS
2758.2%
27.7%
PBYI
More free cash flow
PBYI
PBYI
$345.1M more FCF
PBYI
$14.4M
$-330.7M
ASTS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ASTS
ASTS
PBYI
PBYI
Revenue
$54.3M
$75.5M
Net Profit
$-74.0M
Gross Margin
69.3%
Operating Margin
-175.0%
22.7%
Net Margin
-136.2%
Revenue YoY
2758.2%
27.7%
Net Profit YoY
-106.3%
EPS (diluted)
$0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASTS
ASTS
PBYI
PBYI
Q4 25
$54.3M
$75.5M
Q3 25
$14.7M
$54.5M
Q2 25
$52.4M
Q1 25
$46.0M
Q4 24
$59.1M
Q3 24
$80.5M
Q2 24
$47.1M
Q1 24
$43.8M
Net Profit
ASTS
ASTS
PBYI
PBYI
Q4 25
$-74.0M
Q3 25
$-122.9M
$8.8M
Q2 25
$5.9M
Q1 25
$3.0M
Q4 24
Q3 24
$20.3M
Q2 24
$-4.5M
Q1 24
$-4.8M
Gross Margin
ASTS
ASTS
PBYI
PBYI
Q4 25
69.3%
Q3 25
77.7%
Q2 25
76.5%
Q1 25
77.1%
Q4 24
76.4%
Q3 24
63.9%
Q2 24
77.4%
Q1 24
75.5%
Operating Margin
ASTS
ASTS
PBYI
PBYI
Q4 25
-175.0%
22.7%
Q3 25
-1109.0%
17.6%
Q2 25
12.7%
Q1 25
8.7%
Q4 24
22.6%
Q3 24
27.4%
Q2 24
-4.6%
Q1 24
-5.3%
Net Margin
ASTS
ASTS
PBYI
PBYI
Q4 25
-136.2%
Q3 25
-833.7%
16.2%
Q2 25
11.2%
Q1 25
6.5%
Q4 24
Q3 24
25.2%
Q2 24
-9.6%
Q1 24
-11.0%
EPS (diluted)
ASTS
ASTS
PBYI
PBYI
Q4 25
$0.26
Q3 25
$0.17
Q2 25
$0.12
Q1 25
$0.06
Q4 24
$0.40
Q3 24
$0.41
Q2 24
$-0.09
Q1 24
$-0.10

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASTS
ASTS
PBYI
PBYI
Cash + ST InvestmentsLiquidity on hand
$4.3B
$97.5M
Total DebtLower is stronger
$22.7M
Stockholders' EquityBook value
$2.4B
$130.3M
Total Assets
$5.0B
$216.3M
Debt / EquityLower = less leverage
0.17×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASTS
ASTS
PBYI
PBYI
Q4 25
$4.3B
$97.5M
Q3 25
$2.4B
$94.4M
Q2 25
$96.0M
Q1 25
$93.2M
Q4 24
$101.0M
Q3 24
$96.7M
Q2 24
$96.8M
Q1 24
$107.2M
Total Debt
ASTS
ASTS
PBYI
PBYI
Q4 25
$22.7M
Q3 25
$34.0M
Q2 25
$45.3M
Q1 25
$56.7M
Q4 24
$68.0M
Q3 24
$79.3M
Q2 24
$90.7M
Q1 24
$102.0M
Stockholders' Equity
ASTS
ASTS
PBYI
PBYI
Q4 25
$2.4B
$130.3M
Q3 25
$1.6B
$115.3M
Q2 25
$104.7M
Q1 25
$97.1M
Q4 24
$92.1M
Q3 24
$71.1M
Q2 24
$48.5M
Q1 24
$51.0M
Total Assets
ASTS
ASTS
PBYI
PBYI
Q4 25
$5.0B
$216.3M
Q3 25
$2.6B
$202.9M
Q2 25
$194.9M
Q1 25
$196.2M
Q4 24
$213.3M
Q3 24
$220.7M
Q2 24
$205.0M
Q1 24
$214.1M
Debt / Equity
ASTS
ASTS
PBYI
PBYI
Q4 25
0.17×
Q3 25
0.30×
Q2 25
0.43×
Q1 25
0.58×
Q4 24
0.74×
Q3 24
1.12×
Q2 24
1.87×
Q1 24
2.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASTS
ASTS
PBYI
PBYI
Operating Cash FlowLast quarter
$65.0M
$14.4M
Free Cash FlowOCF − Capex
$-330.7M
$14.4M
FCF MarginFCF / Revenue
-609.0%
19.1%
Capex IntensityCapex / Revenue
728.7%
0.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-790.4M
$41.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASTS
ASTS
PBYI
PBYI
Q4 25
$65.0M
$14.4M
Q3 25
$-64.5M
$9.7M
Q2 25
$14.1M
Q1 25
$3.6M
Q4 24
$15.6M
Q3 24
$11.0M
Q2 24
$1.0M
Q1 24
$11.2M
Free Cash Flow
ASTS
ASTS
PBYI
PBYI
Q4 25
$-330.7M
$14.4M
Q3 25
$-302.9M
$9.7M
Q2 25
$14.1M
Q1 25
$3.6M
Q4 24
$15.6M
Q3 24
$11.0M
Q2 24
$1.0M
Q1 24
FCF Margin
ASTS
ASTS
PBYI
PBYI
Q4 25
-609.0%
19.1%
Q3 25
-2055.0%
17.7%
Q2 25
26.8%
Q1 25
7.7%
Q4 24
26.4%
Q3 24
13.7%
Q2 24
2.1%
Q1 24
Capex Intensity
ASTS
ASTS
PBYI
PBYI
Q4 25
728.7%
0.0%
Q3 25
1617.6%
0.0%
Q2 25
0.0%
Q1 25
0.1%
Q4 24
0.0%
Q3 24
0.0%
Q2 24
0.0%
Q1 24
0.0%
Cash Conversion
ASTS
ASTS
PBYI
PBYI
Q4 25
Q3 25
1.10×
Q2 25
2.41×
Q1 25
1.21×
Q4 24
Q3 24
0.54×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASTS
ASTS

Products$44.4M82%
Other$7.8M14%
Sat Co$2.1M4%

PBYI
PBYI

Segment breakdown not available.

Related Comparisons